Surgical standards in the primary care of melanoma patients

Onkologie

Volumn 26, Issue 3, 2003, Pages 218-222

  Hauschild, Axel ^a,b   Rosien, F ^a   Lischner, S ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Melanoma; Metastasis; Resection margins; Sentinel node; Surgery

Indexed keywords

ALPHA INTERFERON;

ADVANCED CANCER; BIOPSY; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL TRIAL; EXCISION; HEAD AND NECK CANCER; HEALTH CARE COST; HUMAN; IMMUNOHISTOLOGY; LYMPH NODE BIOPSY; LYMPHADENECTOMY; MALIGNANT LENTIGO; MELANOMA; METASTASIS; PATIENT SELECTION; PROGNOSIS; REVIEW; SENTINEL LYMPH NODE; SKIN BIOPSY; SKIN INCISION; SURGICAL TECHNIQUE; WOUND CLOSURE;

BIOPSY; DISEASE PROGRESSION; HUMANS; LYMPH NODES; MELANOMA; NEOPLASM STAGING; SENTINEL LYMPH NODE BIOPSY; SKIN; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0038681083     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000071616     Document Type: Review

References (22)

1. Garbe C: Risikofaktoren für die Entwicklung maligner Melanome und Identifizierung von Risikopersonen im deutschsprachigen Raum. Hautarzt 1995;46:309-314.
2. Kaufmann R: Surgical management of primary melanoma. Clin Exp Dermatol 2000;25:476-481.
3. Veronesi U, Cascinelli N, Adamus J, Balch C, Bandiera D, Barchuk A, Bufalino R, Craig P, de Marsillac J, Durand JC, van Geel AM, Holmstrom H, Hunter JA, Jorgensen OG, Kiss B, Kroon B, Lacour J, Lejeune F, MacKie R, Mechl Z, Mitrov G, Morabito A, Nosek H, Panizzon R, Prade M, Santi P, Slooten E van, Tomin R, Trapeznikov N, Tsanov T, Urist M, Wozniak KD: Thin stage I primary cutaneous malignant melanoma - Comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988;318:1159-1162.
4. Veronesi U, Cascinelli N: Narrow excision (1-cm Margin) A safe procedure for thin cutaneous melanoma. Arch Surg 1991;126:438-441.
5. Balch CM, Urist MM, Karakouis CP, Smith TJ, Temple WJ, Drzewiecki K, Jewell WR, Bartolucci AA, Mihm CM, Barnhill R, Wanebo HJ: Efficacy of 2-cm surgical margins for intermediate thickness melanomas (1 to 4 mm). Ann Surg 1993;218:262-269.
6. Ringborg U, Andersson R, Eldh J, Glaumann B, Hafström L, Jacobsson S, Jönsson P-E, Johansson H, Krysander L, Lagerlöf B: Swedish Melanoma Study Group: Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm. Cancer 1996;77:1809-1814.
7. Heaton KM, Sussman JJ, Gershenwald JE, Lee JE, Reintgen DS, Mansfield PF, Ross MI: Surgical margins and prognostic factors in patients with thick (>4 mm) primary melanoma. Ann Surg Oncol 1998;5:322-328.
8. Ross MI, Balch CM: Surgical treatment of primary melanoma; in Balch CM, Houghton AN, Sober AJ, Soong S-J (eds): Cutaneous Melanoma. St. Louis, Quality Medical Publishing, 1998, pp 141-153.
9. Hauschild A, Lischner S, Christophers E: Operative und adjuvante medikamentöse Therapie des kutanen Melanoms im Kopf-Hals-Bereich. Laryngorhinootologie 2000;79:428-433.
10. Orfanos CE, Jung EG, Rassner G, Wolff HH, Garbe C: Stellungnahme und Empfehlungen der Kommission malignes Melanom der Deutschen Dermatologischen Gesellschaft zur Diagnostik, Behandlung und Nachsorge des malignen Melanoms der Haut. Hautarzt 1994;45:285-291.
11. Breuninger H, Köhler C, Drepper H, Bastian B, Bröcker E-B, Göhl J, Groth W, Hermanek P, Hohenberger W, Lippold A, Kölmel K, Landthaler M, Peters A, Tilgen W: Ist das akrolentiginöse (ALM) maligner als das superfiziell spreitende Melanom (SSM) in einer High-risk-Lokalisation? Hautarzt 1994;45:529-531.
12. Tseng JF, Tanabe KK, Gadd MA, Cosimi AB, Malt RA, Haluska FG, Mihm MC Jr., Sober AJ, Souba WW: Surgical management of primary cutaneous melanomas of the hands and feet. Ann Surg 1997;225:544-550.
13. Breuninger H, Schlagenhauff B, Stroebel W, Schaumburg-Lever G, Rassner G: Patterns of local horizontal spread of melanomas: Consequences for surgery and histopathologic investigation. Am J Surg Pathol 1999;23:1493-1498.
14. Balch CM, Soong SJ, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Ross MI, Jewell WR, Mihm MC, Barnhill RL, Wanebo HJ: Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255-263.
15. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F: Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomised trial. WHO Melanoma Programme. Lancet 1998;351:793-796.
16. Veronesi U, Adamus J, Bandiera DC, Brennhovd IO, Caceres E, Cascinelli N, Claudio F, Ikonopisov RL, Javorskj VV, Kirov S, Kulakowski A, Lacoub J, Lejeune F, Mechl Z, Morabito A, Rode I, Sergeev S, van Slooten E, Szcygiel K, Trapenznikov NN: In-efficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 1977;297:627-630.
17. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, Foshag LJ, Cochran AJ: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-399.
18. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Houghton A Jr., Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen D, Ross MI, Sober A, Thompson JA, Thompson JF: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648.
19. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, Lee JJ, Balch CM, Reintgen DS, Ross MI: Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-983.
20. Rivers JK, Roof MI: Sentinel lymph-node biopsy in melanoma: Is less surgery better? Lancet 1997;350: s1336-1337.
21. Grob JJ, Dreno B, de la Salmoniere P, Delaunay M, Cupissol D, Guillot B, Souteyrand P, Sassolas B, Cesarini JP, Lionnet S, Lok C, Chastang C, Bonerandi JJ: Randomized trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998;351:1905-1910.
22. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH: Interferon alpha2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.